WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in March: TD Cowen 46th Annual Health Care Conference, Boston, MAWednesday, March 4, 2026, Fireside Chat - 9:50 a.m. ET2026 Leerink Partners Global ...

Core Viewpoint - Upstream Bio Inc. shares have experienced a significant decline of over 54% following recent clinical trial results for its asthma treatment, indicating potential concerns among investors regarding the company's competitive positioning in the market [1][3]. Clinical Trial Results - The VALIANT trial reported a statistically significant 56% reduction in the annualized asthma exacerbation rate (AAER) for the 100 mg every 12 weeks dosing compared to placebo, alongside improvements in lung function and a high transition rate of over 90% of eligible patients to the long-term extension study [2]. Analyst Insights - Analyst William Blair noted that while biomarker results for verekitug appeared strong, the lower exacerbation reduction at the 400 mg Q6M dosing raised concerns about its competitive positioning against other candidates in Phase II/III development [3]. - Analyst Matt Phipps commented that the nearly 50% drop in shares is perceived as excessive, as the thymic stromal lymphopoietin (TSLP) space is viewed as a winner-take-all scenario for the first to commercialize a Q6M dosing regimen [4]. Stock Performance and Momentum - Currently, Upstream Bio's stock is trading 10.2% above its 20-day simple moving average (SMA) and 30.5% above its 100-day SMA, indicating strong short-term momentum, with a 12-month surge of 292.24% [4]. - The stock's Relative Strength Index (RSI) is at 45.37, indicating neutral territory, while the MACD is below its signal line, suggesting bearish pressure [5]. Analyst Consensus and Price Targets - The stock holds a Strong Buy rating with an average price forecast of $49.00, with recent analyst actions including targets of $51.00, $43.00, and $40.00 from Mizuho, LifeSci Capital, and Evercore ISI Group respectively [6]. - As of the latest publication, Upstream Bio shares were down 11.33% at $12.69, with key resistance at $33.50 and key support at $12.00 [6].

Core Insights - The VALIANT trial for verekitug showed significant reductions in the annualized asthma exacerbation rate (AAER) by 56% for the 100 mg quarterly dosing and 39% for the 400 mg biannual dosing compared to placebo [2] - The drug demonstrated clinically meaningful improvements in lung function and was well-tolerated, with over 90% of eligible patients transitioning to a long-term extension study [2] - The company plans to initiate registrational trials for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) following regulatory interactions [5] Clinical Trial Results - At week 60, verekitug suppressed exhaled nitric oxide (FeNO) by 20.4 ppb (p<0.0003) for the 100 mg quarterly group and by 26.3 ppb (p<0.0001) for the 400 mg biannual group, representing mean reductions of 43.5% and 44.9% from baseline, respectively [3] - A low-dose treatment group (100 mg biannual) showed a statistically significant effect on AAER but lacked consistent improvements in other endpoints [4] - Statistically significant placebo-adjusted improvements in FEV1 and FeNO were observed at week 24 for both dosing regimens [4] Stock Performance and Analyst Consensus - The stock is currently trading 10.2% above its 20-day simple moving average (SMA) and 30.5% above its 100-day SMA, indicating strong short-term momentum [6] - Over the past 12 months, shares have surged 292.24%, and they are closer to their 52-week highs than lows [6] - The stock carries an Outperform Rating with an average price forecast of $49.00, with recent analyst targets ranging from $40.00 to $51.00 [8]

Top-line Results for the Phase 2 VALIANT Trial in Severe Asthma February 11, 2026 © 2026 Upstream Bio, Inc. No Image Disclaimer This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "continue," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," ...

Core Insights - Upstream Bio, Inc. is set to report top-line results from the Phase 2 VALIANT trial of verekitug, a treatment targeting the TSLP receptor, on February 11, 2026 [1][2] Group 1: Company Overview - Upstream Bio is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders [4] - The company is advancing verekitug, the only known antagonist in clinical development targeting the TSLP receptor, which is involved in inflammatory responses [4] - Upstream Bio aims to address significant unmet needs in patients underserved by current standard care through its development of verekitug [4] Group 2: VALIANT Trial Details - The VALIANT trial is a Phase 2 global, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of verekitug in 478 patients with severe asthma [2] - Participants in the trial were divided into four groups, receiving either 100 mg or 400 mg of verekitug every 24 weeks, 100 mg every 12 weeks, or a placebo, administered subcutaneously [2]

2026 J.P. Morgan Healthcare Conference Rand Sutherland, MD, Chief Executive Officer January 2026 © 2026 Upstream Bio, Inc. No Image Disclaimer This presentation contains forward-looking statements of Upstream Bio, Inc. ("Upstream," "the Company," "we," "us," or "our") that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, results of operations, business strategy ...

Company Overview - Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders [3] - The company is advancing verekitug, a monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), which is involved in inflammatory responses [3] - Verekitug is currently in separate Phase 2 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD) [3] Upcoming Events - Rand Sutherland, MD, CEO of Upstream Bio, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 2:15 p.m. PT [1] - A live webcast of the presentation will be available on Upstream Bio's website, with a replay accessible afterward [2]

Core Insights - Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders [2] Company Overview - Upstream Bio is developing verekitug, the only known antagonist in clinical development targeting the receptor for thymic stromal lymphopoietin (TSLP), which is a key driver of inflammatory responses [2] - The company has advanced verekitug into separate Phase 2 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD) [2] - Upstream Bio aims to address significant unmet needs for patients who are underserved by current standard care [2] Upcoming Events - Rand Sutherland, CEO of Upstream Bio, will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 4:30 p.m. ET [3] - The company will also be present at the 8th Annual Evercore Healthcare Conference on December 4, 2025, at 10:25 a.m. ET [3] - Live webcasts of these presentations will be available on Upstream Bio's website, with replays posted afterward [1][3]

Upstream Bio Conference Call Summary Company Overview - **Company**: Upstream Bio (NasdaqGS:UPB) - **Event**: First annual I&I Summit - **Date**: November 12, 2025 Key Industry Insights Drug Development and Efficacy - Upstream Bio presented positive Phase 2 data for **verekitug**, an antibody targeting the **TSLP receptor**, showing long pharmacodynamic activity with a dosing schedule of Q12 weeks [3][5][6] - The drug demonstrated a **76% reduction** in systemic corticosteroid use and surgery needs in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) [9][10] - The data indicated that there was no plateau in efficacy at 24 weeks, suggesting potential for continued improvement in longer studies [4][8] Clinical Trial Progression - Upstream Bio is advancing towards Phase 3 trials for both CRSwNP and severe asthma, with plans to analyze data from both indications contemporaneously to inform dose selection [11][12] - The company aims to initiate Phase 3 programs as quickly as possible, contingent on data analysis and regulatory feedback [31] Competitive Landscape - Upstream Bio differentiates itself from competitors by targeting the **TSLP receptor** rather than the ligand, which is the approach taken by other companies [34][35] - The competitive landscape includes drugs from GSK and ILOS, which are reportedly behind Upstream Bio in development timelines [32][34] Additional Important Points Pharmacodynamics and Dosing - The pharmacodynamic profile of verekitug suggests that it maintains receptor occupancy for up to **24 weeks** after the last dose, which is critical for sustained efficacy [24][22] - The company is exploring the potential for extended dosing intervals (Q24 weeks) while ensuring that efficacy is not compromised [17][22] Regulatory Considerations - Upstream Bio is focused on obtaining robust data to support regulatory negotiations, with a primary endpoint of asthma exacerbation reduction set at **50% or greater** [26][28] - The company is preparing for potential discussions with regulators regarding the design of future trials, including considerations for secondary endpoints like lung function improvement [30][31] Future Data Releases - Upcoming data from the Phase 2 trials is expected in Q1, with plans to present findings at major medical meetings such as QuadAI and ATS in the first half of the following year [38] This summary encapsulates the critical insights and developments discussed during the Upstream Bio conference call, highlighting the company's strategic direction and competitive positioning within the biotech industry.

Core Insights - Upstream Bio, Inc. reported positive top-line results from the VIBRANT Phase 2 trial of verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP), demonstrating significant efficacy and a favorable safety profile [1][5] - The company is on track to report results from the VALIANT Phase 2 trial in severe asthma in the first quarter of 2026, with ongoing enrollment in the VENTURE Phase 2 trial for chronic obstructive pulmonary disease (COPD) [1][4][12] - Financial results for Q3 2025 show a net loss of $33.7 million, with increased research and development expenses primarily related to verekitug programs [8][10][19] Recent Business Highlights - The VIBRANT Phase 2 trial met its primary endpoint with a statistically significant reduction in placebo-adjusted endoscopic nasal polyp score of -1.8 (p<0.0001) [5] - Key secondary endpoints showed a reduction in nasal congestion score of -0.8 (p=0.0003) and a 76% (p=0.03) reduction in the need for surgery or systemic corticosteroids [5] - Structural and mechanistic data presented at the European Respiratory Society Congress highlighted verekitug's unique mechanism of action in disrupting TSLP signaling [2][12] Upcoming Milestones - Top-line data from the VALIANT Phase 2 trial in severe asthma is expected in Q1 2026, with the trial designed to assess efficacy and safety in extended dosing intervals of 12 and 24 weeks [4] - Enrollment is ongoing in the VENTURE Phase 2 trial for COPD, with the first patient dosed in July 2025 [1][12] Financial Overview - As of September 30, 2025, Upstream Bio had cash, cash equivalents, and short-term investments totaling $372.4 million, expected to fund operations through 2027 [8] - Research and development expenses for Q3 2025 were $33.0 million, up from $15.4 million in the same period in 2024, reflecting increased clinical and manufacturing costs [8][10] - General and administrative expenses rose to $5.5 million in Q3 2025, compared to $4.1 million in Q3 2024, driven by personnel-related costs [9]